Actinogen Medical (ASX:ACW)
ASX announcement history & article coverage
Transparent by design.
Announcments by Actinogen Medical (ASX:ACW) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of buy-back - ACW
ACW AAIC poster presentation of XanaMIA trial baseline data
ACW senior management presentation at AAIC & internationally
Becoming a substantial holder
Appendix 3Y x 5
Application for quotation of securities - ACW
Results of Meeting
Application for quotation of securities - ACW
ACW third positive XanaMIA trial data committee review
Actinogen Medical's XanaMIA Alzheimer's trial receives third positive safety recommendation; final results due November 2026
ACW presents XanaMIA population and screening data at ADRF
Actinogen receives positive scientific advice from EMA
Actinogen secures positive EMA advice aligned with FDA for Alzheimer's drug Xanamem development
Application for quotation of securities - ACW
Letter to Shareholders, Notice of GM & Proxy Form
Application for quotation of securities - ACW
ACW CEO options exercise and expiry reminder
Appendix 3Y - Dr Steven Gourlay
Application for quotation of securities - ACW
Application for quotation of securities - ACW
Notification of cessation of securities - ACW
Correction-March2026 quarterly activity report & Appendix 4C
Actinogen Medical reports positive interim XanaMIA trial results, $16.8M capital raise, and extended cash runway
ACW December 2025 quarterly activity report & Appendix 4C
Actinogen Medical reports positive interim XanaMIA trial results, $16.8M capital raise, and extended cash runway
